After a Successful 2021, Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off 2022 With New Media Strategy, Plans for Clinical Study Advancements
Lexaria has multiple studies planned that will commence early in 2022 DehydraTECH increases Lexaria’s ability to leverage multiple markets, including…